Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

When Sanofi cuts the price as of Jan. 1, Lantus will cost about $64 per vial. The company also announced a price cap that ensures no patient will pay more than $35 for a monthly supply of Lantus.

The cancer scare over Sanofi-Aventis' Lantus shows just how much power over a company's drug sales -- and its stock -- are now concentrated in the hands of a tiny number of experts.

In the flap over whether Sanofi-Aventis' Lantus diabetes drug has an association with cancer, cynicism seems to be winning. Sanofi's stock (see graph) seems not to have recovered from reports that ...

Sanofi’s Lantus, its most commonly prescribed insulin, will sell for $35 a month through GoodRx Holdings Inc. in a deal that signals the drug-discount site’s growing business with large pharma ...

Sanofi SA said on Thursday it will cut U.S. list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly and Co .

Sanofi's rivals in the insulin field are nipping at its heels – Lantus sales dipped 5 per cent in the first half of 2015, and analysts don't expect Toujeo to make up for its decline.

Sanofi SNY announced up to a 78% cut in the list price of its most popular insulin, Lantus, following the likes of rival Novo Nordisk NVO and Eli Lilly LLY.Similar to Lilly, Sanofi also said it is ...

This collaboration builds on Sanofi’s recent announcement to lower the list price for Lantus and cap out-of-pocket costs at $35 for all patients with commercial insurance, which goes into effect ...

Sanofi is based in Paris. Lantus will lose U.S. patent protection in February 2015, and Sanofi and Lilly have been working on experimental insulin therapies to replace it.

The FDA approved Sanofi’s daily diabetes drug Toujeo Wednesday, but the new treatment does not appear to pack a profile that will pull payers or physicians away from Lantus to generic-free Toujeo.

Sanofi (SNY) plans to lower the prices of its most widely used insulin Lantus by upto 78% in the United States, effective January 2024.